NCT01167972

Brief Summary

The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2010

Geographic Reach
1 country

101 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 20, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 22, 2010

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2010

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
Last Updated

September 10, 2012

Status Verified

September 1, 2012

Enrollment Period

2 years

First QC Date

July 20, 2010

Last Update Submit

September 7, 2012

Conditions

Keywords

M + mutationNon Small Cell Lung Cancer adenocarcinomaTo determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma

Outcome Measures

Primary Outcomes (1)

  • The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma

    At baseline

Secondary Outcomes (3)

  • Describe the therapeutic management according to the mutational status (EGFR M +, EGFR M- and Mx).

    12 months / At each visit

  • Describe the therapeutic management of patients with EGFR M +.

    12 months / At each visit

  • Describe the clinical course of patients EGFR-M +, treated for first-line treatment, and then 2nd line treatment, until 31-AUG-2012

    12 months / At each visit

Study Arms (1)

1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patient with NSCLC adenocarcinoma confirmed by histologyPatient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed

You may qualify if:

  • Patient with lung cancer (Non Small Cell Lung Cancer adenocarcinoma)
  • Patient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed

You may not qualify if:

  • Assessment of mutational status of EGFR is not done

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (101)

Research Site

Abbeville, France

Location

Research Site

Aix-en-Provence, France

Location

Research Site

Amilly, France

Location

Research Site

Angers, France

Location

Research Site

Antibes, France

Location

Research Site

Arras, France

Location

Research Site

Aulnay-sous-Bois, France

Location

Research Site

Auxerre, France

Location

Research Site

Bastia, France

Location

Research Site

Bayonne, France

Location

Research Site

Béthune, France

Location

Research Site

Blois, France

Location

Research Site

Bobigny, France

Location

Research Site

Bois-Guillaume, France

Location

Research Site

Bonneville, France

Location

Research Site

Bordeaux, France

Location

Research Site

Boulogne-sur-Mer, France

Location

Research Site

Bourg-en-Bresse, France

Location

Research Site

Brest, France

Location

Research Site

Brive-la-Gaillarde, France

Location

Research Site

Bron, France

Location

Research Site

Caen, France

Location

Research Site

Chalon-sur-Saône, France

Location

Research Site

Chauny, France

Location

Research Site

Clermont-Ferrand, France

Location

Research Site

Colmar, France

Location

Research Site

Compiègne, France

Location

Research Site

Creil, France

Location

Research Site

Créteil, France

Location

Research Site

Dijon, France

Location

Research Site

Douai, France

Location

Research Site

Draguignan, France

Location

Research Site

Fougères, France

Location

Research Site

Gap, France

Location

Research Site

Granville, France

Location

Research Site

La Roche-sur-Yon, France

Location

Research Site

La Rochelle, France

Location

Research Site

La Seyne-sur-Mer, France

Location

Research Site

La Source, France

Location

Research Site

La Tronche, France

Location

Research Site

Le Plessis-Robinson, France

Location

Research Site

Lens, France

Location

Research Site

Levallois-Perret, France

Location

Research Site

Libourne, France

Location

Research Site

Liévin, France

Location

Research Site

Lille, France

Location

Research Site

Limoges, France

Location

Research Site

Longjumeau, France

Location

Research Site

Lyon, France

Location

Research Site

Mantes-la-Jolie, France

Location

Research Site

Marseille, France

Location

Research Site

Meaux, France

Location

Research Site

Mont-de-Marsan, France

Location

Research Site

Mont-Saint-Martin, France

Location

Research Site

Montauban, France

Location

Research Site

Montivilliers, France

Location

Research Site

Montpellier, France

Location

Research Site

Moulins, France

Location

Research Site

Nevers, France

Location

Research Site

Niort, France

Location

Research Site

Nîmes, France

Location

Research Site

Oloron-Sainte-Marie, France

Location

Research Site

Paris, France

Location

Research Site

Pau, France

Location

Research Site

Pessac, France

Location

Research Site

Pierre-Bénite, France

Location

Research Site

Poitiers, France

Location

Research Site

Pontivy, France

Location

Research Site

Pontoise, France

Location

Research Site

Pringy, France

Location

Research Site

Privas, France

Location

Research Site

Redon, France

Location

Research Site

Reims, France

Location

Research Site

Rennes, France

Location

Research Site

Roanne, France

Location

Research Site

Rouen, France

Location

Research Site

Saint-Aubin-lès-Elbeuf, France

Location

Research Site

Saint-Brieuc, France

Location

Research Site

Saint-Denis, France

Location

Research Site

Saint-Herblain, France

Location

Research Site

Saint-Pierre-des-Corps, France

Location

Research Site

Saint-Priest-en-Jarez, France

Location

Research Site

Saint-Quentin, France

Location

Research Site

Saintes, France

Location

Research Site

Salouël, France

Location

Research Site

Sarrebourg, France

Location

Research Site

Soissons, France

Location

Research Site

Ste Clotilde, France

Location

Research Site

Ste Feyre, France

Location

Research Site

Strasbourg, France

Location

Research Site

Toulon, France

Location

Research Site

Toulouse, France

Location

Research Site

Tourcoing, France

Location

Research Site

Tours, France

Location

Research Site

Trappes, France

Location

Research Site

Valence, France

Location

Research Site

Vendôme, France

Location

Research Site

Verdun, France

Location

Research Site

Villejuif, France

Location

Research Site

Villenave-d'Ornon, France

Location

Research Site

Yerres, France

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Corrine Bernaud, Medical Director

    AstraZeneca

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 20, 2010

First Posted

July 22, 2010

Study Start

September 1, 2010

Primary Completion

September 1, 2012

Study Completion

September 1, 2012

Last Updated

September 10, 2012

Record last verified: 2012-09

Locations